Why Is LEGEND BIOTECH CORP ADR (LEGN) Stock Down Today?

Legend Biotech (LEGN) shares fell 5.35% to $19.32 as a wave of price target reductions followed the company’s third-quarter earnings release. The stock had previously risen 12.2% over the last eight sessions, but recent analyst actions have pressured the valuation.

What Happened

Legend Biotech reported Q3 2026 results showing CARVYKTI sales rose 36% to $710 million, while adjusted net income reached $55.6 million. Management revised the Q4 gross margin outlook to the high 50% range and targets 2026 adjusted profitability. Despite the strong revenue growth, total sales of $359.5 million missed the $361.619 million estimate, although adjusted EPS of $0.14 beat the $0.00 estimate.

Following the report, several major banks lowered their price targets. RBC Capital cut its target to $50 from $56, while Morgan Stanley reduced its target to $43 from $49. Oppenheimer lowered its target to $25 from $40, and Barclays cut its target to $61 from $68. H.C. Wainwright reiterated its buy rating without a new price target. Additionally, FMR LLC added 19.07 million shares to its portfolio.

What The Data Shows

The stock opened at $20.85, a 2.2% gap up from the prior close of $20.41. It hit a session high of $20.89 at 8:55 AM ET before sliding to a low of $19.24 at 9:55 AM ET. Volume stood at 0.4 million shares, which is 0.2 times the three-month daily average. The company has a market cap of $4.7 billion and a beta of 0.55. Revenue is up 59.5% year-to-date, but the company remains unprofitable with a trailing twelve-month EPS of -0.50 and a net margin of -7.2%. The 52-week range is $16.24 to $37.50.

Recent insider activity includes two sales totaling $309,000 in the last 90 days, with no buys recorded. Director Corazon D. Sanders sold shares on September 29, 2026, and CFO Carlos E. Santos sold on September 21, 2026. The 30-day average sentiment score is 54, while the last seven days average is 50, indicating a slight deterioration in mood.

What To Watch

Investors will monitor the company’s progress toward its 2026 adjusted profitability target and how the market digests the recent price target cuts from major banks.